Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

289
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
289
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

474
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
474
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

555
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
555
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
145

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence and Consensus Based Guidelines for Imaging in Tubercular Choroiditis. Multimodal imaging in Uveitis (MUV) Taskforce: Report 17.

Ophthalmology. Retina·2026
Same author

Vogt-Koyanagi-Harada disease frequency around the globe: a systematic review and meta-analysis.

Eye (London, England)·2026
Same author

Reply to Comment on: Imaging Biomarkers for Early Differentiation of Candida and Aspergillus Endogenous Fungal Endophthalmitis: Multicenter Optical Coherence Tomography-Based Analysis.

American journal of ophthalmology·2026
Same author

Eales' disease revisited: Current understanding of etiopathogenesis, multimodal imaging, and treatment strategies.

Indian journal of ophthalmology·2026
Same author

Optical Coherence Tomography (OCT) Features of Inactive Multifocal Choroiditis With Panuveitis and Punctate Inner Choroidopathy (MFCPU/PIC) Lesions.

American journal of ophthalmology·2026
Same author

Evidence and Consensus-Based Guidelines in Vogt-Koyanagi-Harada Disease. Multimodal Imaging in Uveitis (MUV) Taskforce Report 16.

Ophthalmology. Retina·2026
Same journal

Reply to Comment on Visual Field Progression in Glaucoma Patients with Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Comment on: "Safety and efficiency reducing retinopathy of prematurity guideline sensitivity: an external validation using a large US-based dataset".

American journal of ophthalmology·2026
Same journal

Reply to Comment on "Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease".

American journal of ophthalmology·2026
Same journal

Comment on: Visual Field Progression in Glaucoma Patients With Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Corneal sensitivity changes and nerve plexus abnormalities in noninfectious anterior uveitis.

American journal of ophthalmology·2026
Same journal

Role of Menopausal Hormone Therapy on Strabismus, Strabismus Surgery, and Reoperation Rates.

American journal of ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Jul 16, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.3K

The Humira in Ocular Inflammations Taper (HOT) Study.

Francesco Pichi1, Scott D Smith1, Debra A Goldstein2

  • 1From the Eye Institute (F.P., S.D.S., A.A., P.N.), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Cleveland Clinic Lerner College of Medicine (F.P., S.D.S., A.A., P.N.), Case Western Reserve University , Cleveland, Ohio, USA.

American Journal of Ophthalmology
|September 21, 2023
PubMed
Summary
This summary is machine-generated.

Younger age, faster adalimumab tapering, and shorter remission periods increase noninfectious uveitis relapse risk. Slow dose reduction and longer remission are advised for patients undergoing adalimumab tapering.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

222
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
06:29

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

2.4K

Related Experiment Videos

Last Updated: Jul 16, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

222
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
06:29

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

2.4K

Area of Science:

  • Ophthalmology
  • Immunology
  • Rheumatology

Background:

  • Noninfectious uveitis (NIU) is a chronic inflammatory eye condition.
  • Adalimumab is a common biologic therapy for achieving remission in NIU.
  • Tapering adalimumab requires careful consideration to prevent disease recurrence.

Purpose of the Study:

  • To identify factors influencing relapse risk in noninfectious uveitis patients after adalimumab dose reduction.
  • To evaluate the impact of patient demographics and treatment parameters on uveitis recurrence post-adalimumab tapering.

Main Methods:

  • Retrospective multicenter study involving 328 patients with NIU treated with adalimumab.
  • Data collected included patient demographics, NIU type, disease history, remission duration, and adalimumab tapering schedule.
  • Statistical analysis identified predictors of uveitis recurrence rate.

Main Results:

  • Recurrence was observed in 39.6% of patients, with younger patients (mean age 29.4 years) experiencing higher rates.
  • Faster adalimumab tapering schedules were significantly associated with increased recurrence risk (HR=1.23).
  • Longer periods of inactivity before tapering (mean 100.8 weeks) were linked to a lower recurrence rate (HR=0.97).

Conclusions:

  • Patient age, race, and duration of remission on adalimumab are critical factors during dose tapering.
  • A slow, gradual tapering strategy for adalimumab is recommended to minimize noninfectious uveitis relapse.
  • Personalized tapering protocols considering individual patient factors may improve long-term outcomes.